31843258|t|Presynaptic dopaminergic function in early-onset Alzheimer's disease: an FP-CIT image study.
31843258|a|We aimed to investigate whether amyloid-beta (Abeta) positive early-onset Alzheimer's disease (EOAD) patients have presynaptic dopaminergic deficits on in vivo 18F-FP-CIT PET imaging. We enrolled 34 EOAD patients and 9 cognitively normal controls (NC), all of whom underwent 18F-florbetaben and 18F-FP-CIT PET at Samsung Medical Center. We assessed motor symptoms using Unified Parkinson's Disease Rating Scale (UPDRS) and divided the EOAD patients into 2 groups using a UPDRS cutoff of 10. We compared regional florbetaben and FP-CIT uptake across the NC and the 2 EOAD groups with lower and higher UPDRS and investigated the associations between regional florbetaben or FP-CIT uptake and UPDRS in EOAD patients. Among the 30 EOAD patients who were Abeta positive on florbetaben PET, the higher UPDRS (>10) group (n = 9) had a longer disease duration (7.2 +- 3.3 vs. 4.1 +- 1.8, p = 0.002), and had a tendency to have lower Mini-Mental State Examination (9.6 +- 7.9 vs. 15.0 +- 6.0, p = 0.052) than the lower UPDRS (<=10) group (n = 21). Across the NC and the 2 EOAD groups, there were no significant differences in FP-CIT uptake in caudate (p = 0.122) and putamen (p = 0.685) or florbetaben uptake in midbrain (p = 0.890). Finally, regression analyses showed that UPDRS was not associated with FP-CIT uptake in caudate (p = 0.913) or putamen (p = 0.407), or with florbetaben PET uptake in caudate (p = 0.553), putamen (p = 0.617), midbrain (p = 0.843), or global cortex (p = 0.658). This study showed that parkinsonian signs in EOAD patients may be related with mechanisms other than presynaptic dopaminergic deficit. Our finding is clinically important because it suggests that L-dopa treatment in EOAD with parkinsonian signs may not improve motor symptoms.
31843258	12	24	dopaminergic	Disease	MESH:D009422
31843258	49	68	Alzheimer's disease	Disease	MESH:D000544
31843258	73	79	FP-CIT	Chemical	MESH:C087552
31843258	125	137	amyloid-beta	Gene	351
31843258	139	144	Abeta	Gene	351
31843258	167	186	Alzheimer's disease	Disease	MESH:D000544
31843258	188	192	EOAD	Disease	MESH:D000544
31843258	194	202	patients	Species	9606
31843258	220	232	dopaminergic	Disease	MESH:D009422
31843258	253	263	18F-FP-CIT	Chemical	MESH:C087552
31843258	292	296	EOAD	Disease	MESH:D000544
31843258	297	305	patients	Species	9606
31843258	368	383	18F-florbetaben	Chemical	MESH:C527756
31843258	388	398	18F-FP-CIT	Chemical	MESH:C087552
31843258	471	490	Parkinson's Disease	Disease	MESH:D010300
31843258	528	532	EOAD	Disease	MESH:D000544
31843258	533	541	patients	Species	9606
31843258	605	616	florbetaben	Chemical	MESH:C527756
31843258	621	627	FP-CIT	Chemical	MESH:C087552
31843258	659	663	EOAD	Disease	MESH:D000544
31843258	750	761	florbetaben	Chemical	MESH:C527756
31843258	765	771	FP-CIT	Chemical	MESH:C087552
31843258	792	796	EOAD	Disease	MESH:D000544
31843258	797	805	patients	Species	9606
31843258	820	824	EOAD	Disease	MESH:D000544
31843258	825	833	patients	Species	9606
31843258	843	848	Abeta	Gene	351
31843258	861	872	florbetaben	Chemical	MESH:C527756
31843258	1156	1160	EOAD	Disease	MESH:D000544
31843258	1210	1216	FP-CIT	Chemical	MESH:C087552
31843258	1274	1285	florbetaben	Chemical	MESH:C527756
31843258	1389	1395	FP-CIT	Chemical	MESH:C087552
31843258	1458	1469	florbetaben	Chemical	MESH:C527756
31843258	1601	1613	parkinsonian	Disease	MESH:D010300
31843258	1623	1627	EOAD	Disease	MESH:D000544
31843258	1628	1636	patients	Species	9606
31843258	1691	1711	dopaminergic deficit	Disease	MESH:D009461
31843258	1774	1780	L-dopa	Chemical	MESH:D007980
31843258	1794	1798	EOAD	Disease	MESH:D000544
31843258	1804	1816	parkinsonian	Disease	MESH:D010300
31843258	Association	MESH:C527756	MESH:D000544
31843258	Negative_Correlation	MESH:C087552	MESH:D009422
31843258	Association	MESH:D007980	MESH:D000544
31843258	Association	MESH:C087552	MESH:D000544
31843258	Association	MESH:D000544	351
31843258	Positive_Correlation	MESH:C527756	351

